Final Melanoma Survival Data Headed to ESMO, Faron Confirms
Faron will present final melanoma survival data at the ESMO congress — a mature dataset that could shape advanced cutaneous melanoma conversations.
Topic
Pipeline
Topic
Pipeline
2026 Dermatology Update Roundup Lands; Details Thin in Feed
A 2026 dermatology approvals-and-pipelines roundup is circulating via Medical Professionals Reference, but the syndicated feed ex…
Trispecific Antibody Emerges in Atopic Dermatitis Pipeline
HCPLive covers a novel trispecific molecule in development for moderate-to-severe atopic dermatitis — a three-pathway antibody de…
Sanofi-Regeneron Expand Antibody Pact to Four IL-13, IL-4 Candidates
Sanofi will pay Regeneron $1 billion up front plus up to $7 billion in milestones to co-develop four long-acting antibodies targe…
EVO301, a Long-Acting Candidate, Shows Early Promise in Atopic Dermatitis
Long-acting investigational therapy EVO301 showed promise in a proof-of-concept atopic dermatitis study, an early signal that ext…
Immunocore Completes 540-Patient Enrollment in Phase 3 TEBE-AM Melanoma Trial
Immunocore hit target enrollment of 540 patients in the Phase 3 TEBE-AM trial of tebentafusp in HLA-A*02:01-positive advanced mel…
Pfizer Phase II Results Advance Tilrekimig Into Pivotal Trials
Pfizer advances tilrekimig into pivotal atopic dermatitis and asthma trials on the strength of Phase II AD data, deepening its ty…
AbbVie Moves Zumilokibart Into Phase 3 Atopic Dermatitis Trials
AbbVie advances its IL-13-targeting biologic zumilokibart into Phase 3 atopic dermatitis trials, adding a pipeline candidate alon…
AbbVie's zumilokibart Hits Phase 2 Atopic Dermatitis Endpoint
AbbVie reports zumilokibart met its primary endpoint in a phase 2 atopic dermatitis trial, advancing a key pipeline asset toward…
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
Dermatology Times' Q3 2026 review rounds up FDA approvals and clinical readouts in dermatology; the syndicated headline did not i…